Semaglutide and kidney disease: what FLOW found

A kidney benefit in a specific population

FLOW was a randomized trial comparing weekly injected semaglutide with placebo in people who had both type 2 diabetes and chronic kidney disease. It enrolled 3,533 participants. The trial’s kidney entry criteria included measures of kidney filtration and albumin in the urine, rather than a general report of having a kidney problem.²

That distinction matters when the result appears in an advertisement. A study in people with diabetes and chronic kidney disease does not establish the same benefit for someone with normal kidney function who is seeking weight loss. Nor does it show that every kidney condition responds the same way.

The study used a defined injected product and treatment protocol. It was not an outcomes trial of every preparation sold under the semaglutide name. If a program uses kidney benefits to promote a particular product, ask the clinician which evidence supports that product and the condition being treated.

What FLOW measured

The primary outcome combined kidney failure, a substantial sustained reduction in estimated kidney filtration, and death from kidney-related or cardiovascular causes. Kidney failure included dialysis, transplantation or a very low filtration level. It was therefore a composite outcome, not simply a count of people who started dialysis.²

There were 331 first primary-outcome events in the semaglutide group and 410 in the placebo group. The reported hazard ratio was 0.76, with a 95% confidence interval of 0.66 to 0.88. The authors described the relative reduction in risk as 24%. Median follow-up was 3.4 years.²

You may see the result shortened to “24% fewer kidney problems.” That loses important information. The primary outcome included cardiovascular death, and the percentage describes a relative comparison over the trial period. It is not the proportion of participants whose kidney disease was cured.

The trial stopped early after a prespecified interim analysis recommended it. This belongs in a description of the evidence because the duration and design affect how the result is interpreted. The study was funded by Novo Nordisk.²

What the result does not establish

FLOW does not show that semaglutide reverses every form of kidney disease. It does not replace a person’s existing kidney care, establish which other medicines should be stopped, or tell an individual patient how their filtration result will change. Those are different clinical questions.

Be especially careful with an apparently simple laboratory comparison. A single kidney result and a trial measuring events over years are different kinds of information. Ask the clinician which measures matter for your situation and what would count as a meaningful change.

For someone whose main concern is weight management, the right question is whether a particular kidney finding changes the treatment decision or the monitoring plan. The answer needs the person’s records; it cannot be inferred from the headline benefit alone.

Why a kidney warning can coexist with a kidney benefit

The OZEMPIC label also warns about acute kidney injury due to volume depletion. It describes reports, including some requiring dialysis, and notes that most occurred in patients with nausea, vomiting or diarrhea leading to dehydration. The label calls for monitoring kidney function when adverse reactions could lead to volume depletion, especially during initiation and escalation.¹

That warning addresses a different event and timescale from FLOW’s long-term outcome. A medicine can improve one important outcome in a studied population and still carry a warning about a different pathway to harm. Calling the drug simply “good” or “bad” for the kidneys obscures that distinction.

If vomiting or diarrhea is making it difficult to stay hydrated, contact the prescribing team for advice rather than treating the FLOW result as reassurance that kidney problems are impossible. This page does not provide a fluid target or a medication adjustment.

Questions for the prescribing and kidney-care teams

Ask why semaglutide is being considered in your case: diabetes care, a kidney-related indication, weight management or another approved use. Then ask which team will follow kidney function, how results will be shared and who should be contacted when side effects interfere with drinking or eating.

If more than one clinician is involved, clarify who coordinates changes. A telehealth intake and a kidney specialist visit can each contain useful information, but neither helps if the other team never receives it. Ask the program how you can obtain and share the treatment record. For an example of the service questions to check, our LifeMD review distinguishes ongoing care, lab arrangements and separate medication costs. It does not assess kidney outcomes.

For coverage, use the actual prescription and indication rather than the phrase “kidney protection.” A trial result supports a medical discussion; it is not a coverage determination. Ask the provider what documentation it can supply and ask the plan what it requires.